IS7911A - Ímídasólafleiður með sækni í alfa 2 viðtakavirkni - Google Patents

Ímídasólafleiður með sækni í alfa 2 viðtakavirkni

Info

Publication number
IS7911A
IS7911A IS7911A IS7911A IS7911A IS 7911 A IS7911 A IS 7911A IS 7911 A IS7911 A IS 7911A IS 7911 A IS7911 A IS 7911A IS 7911 A IS7911 A IS 7911A
Authority
IS
Iceland
Prior art keywords
unsubstituted
substituted
affinity
alpha
prodrug forms
Prior art date
Application number
IS7911A
Other languages
English (en)
Other versions
IS2282B (is
Inventor
Järvinen Tomi
Niemi Riku
Huuskonen Juhani
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of IS7911A publication Critical patent/IS7911A/is
Publication of IS2282B publication Critical patent/IS2282B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IS7911A 2002-12-05 2005-06-23 Ný lyfefnasambönd með alfa2viðtakavirkni IS2282B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä
PCT/FI2003/000933 WO2004050635A2 (en) 2002-12-05 2003-12-05 Imidazol derivatives having affinity for alpha 2 receptors activity

Publications (2)

Publication Number Publication Date
IS7911A true IS7911A (is) 2005-06-23
IS2282B IS2282B (is) 2007-09-15

Family

ID=8565048

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7911A IS2282B (is) 2002-12-05 2005-06-23 Ný lyfefnasambönd með alfa2viðtakavirkni

Country Status (27)

Country Link
US (1) US7759496B2 (is)
EP (1) EP1572198B1 (is)
JP (1) JP4667042B2 (is)
KR (1) KR20050114603A (is)
CN (1) CN100560070C (is)
AT (1) ATE323484T1 (is)
BR (1) BR0317024A (is)
CA (1) CA2508335C (is)
CY (1) CY1105699T1 (is)
DE (1) DE60304741T2 (is)
DK (1) DK1572198T3 (is)
EA (1) EA008251B1 (is)
ES (1) ES2262031T3 (is)
FI (1) FI20022159A0 (is)
HR (1) HRP20050617B1 (is)
IL (1) IL168882A (is)
IS (1) IS2282B (is)
ME (1) ME00521B (is)
MX (1) MXPA05005963A (is)
NO (1) NO330392B1 (is)
NZ (1) NZ540466A (is)
PL (1) PL216530B1 (is)
PT (1) PT1572198E (is)
RS (1) RS52571B (is)
SI (1) SI1572198T1 (is)
WO (1) WO2004050635A2 (is)
ZA (1) ZA200504533B (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
CN101374830A (zh) 2005-08-25 2009-02-25 先灵公司 α2C肾上腺素受体激动剂
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
JP4647785B2 (ja) * 1998-09-28 2011-03-09 オリオン コーポレーション 脊椎内、髄腔内または硬膜外投与用医薬の製造における３−（１ｈ−イミダゾール−４−イルメチル）−インダン−５−オールの用途
CA2388979C (en) * 1999-10-29 2010-09-14 Orion Corporation Treatment or prevention of hypotension and shock with use of an imidazole derivative
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) * 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use

Also Published As

Publication number Publication date
HRP20050617A2 (en) 2005-10-31
ATE323484T1 (de) 2006-05-15
IL168882A (en) 2010-05-31
IS2282B (is) 2007-09-15
EA200500922A1 (ru) 2005-12-29
DE60304741T2 (de) 2007-04-12
JP4667042B2 (ja) 2011-04-06
MXPA05005963A (es) 2005-08-18
EP1572198A2 (en) 2005-09-14
ES2262031T3 (es) 2006-11-16
NO20053302D0 (no) 2005-07-05
RS52571B (en) 2013-04-30
CA2508335A1 (en) 2004-06-17
DE60304741D1 (de) 2006-05-24
PL216530B1 (pl) 2014-04-30
CN100560070C (zh) 2009-11-18
CN1735409A (zh) 2006-02-15
FI20022159A0 (fi) 2002-12-05
RS20050428A (en) 2007-08-03
NO20053302L (no) 2005-07-05
EP1572198B1 (en) 2006-04-19
CY1105699T1 (el) 2010-12-22
WO2004050635A3 (en) 2004-09-02
ZA200504533B (en) 2006-03-29
BR0317024A (pt) 2005-10-25
NO330392B1 (no) 2011-04-04
DK1572198T3 (da) 2006-07-03
NZ540466A (en) 2008-04-30
WO2004050635A2 (en) 2004-06-17
SI1572198T1 (sl) 2006-08-31
HRP20050617B1 (hr) 2013-07-31
PL377530A1 (pl) 2006-02-06
US7759496B2 (en) 2010-07-20
EA008251B1 (ru) 2007-04-27
AU2003302622A1 (en) 2004-06-23
PT1572198E (pt) 2006-08-31
US20060178417A1 (en) 2006-08-10
ME00521B (me) 2011-10-10
JP2006509780A (ja) 2006-03-23
CA2508335C (en) 2011-09-13
KR20050114603A (ko) 2005-12-06

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
EA200601235A1 (ru) Производные тиазола
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
RS49850B (sr) Derivati 1,4-benzotiazepin-1,1-dioksida supstituisani radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
BR0315405A (pt) Compostos inibidores da integrase tricìclica pré-organizados
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
DK0784054T3 (da) 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
DK1008592T3 (da) Cykliske amidderivater, som inhiberer cathepsin K
NO20054092L (no) Nye tricykliske azepinforbindelser, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
PT1427727E (pt) Compostos que inibem a libertacao de citocinas inflamatorias
IS7911A (is) Ímídasólafleiður með sækni í alfa 2 viðtakavirkni
EG24927A (en) (diarylmethyl)-1-piperazinyl derivatives
EP1151993A4 (en) CYCLIC AMINE DERIVATIVES AND THEIR APPLICATIONS
ATE268769T1 (de) Pyrimidinderivate mit antitumor-wirkung